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1. Introduction 
Sweet syndrome (SS) was first described by Robert Sweet in 1964 as acute febrile 
neutrophilic dermatosis (Sweet, 1966). Despite of the descriptive value of this denomination 
and the advice of Robert Sweet to keep it, the eponymous became prevalent on the time. SS 
was the first neutrofilic dermatosis (ND) described and it represents the paradigm of them. 
There are three key points of SS that are of interest not only for the dermatologists but also 
for the general practitioners: a) its marked clinical manifestations, b) the potential systemic 
repercussion of neutrophilic reaction, and c) its association with extracutaneos diseases, 
especially with malignancies. 
2. Definition and classification 
SS is a neutrophilic dermatosis characterized by specific clinical and histopathological 
manifestations. In fact, the best way of defining SS is based on its diagnostic criteria. 
Typically, SS appears abruptly with multiple, edematous, tender red plaques that are 
distributed bilaterally but asymmetrically in a febrile patient. The dermatopathological 
image shows a neutrophilic diffuse infiltrate without vasculitis located in upper dermis. 
Besides this typical picture, several clinical and histopathological variants have been 
described (table 1). The current classification of SS is based on the associated or trigger 
conditions and has clinical value for the management of these patients (table 2). 
 
Transitional forms with other neutrophlic dermatosis 
Located forms: dorsal hands and facial 
Chronic recurrent neutrophilic dermatosis 
Histiocytoid Sweet syndrome 
Table 1. Main clinical and histopathological subtypes of Sweet syndrome 
 
Idiopatic 
Parainflammatory 
Paraneoplastic 
Drug-induced 
Associated to pregnancy 
Table 2. Classification of Sweet syndrome 
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3. Epidemiology 
There is not reliable data regarding the incidence and prevalence of SS in general 
population. This relies on the fact that SS is an infrequent condition and the available data 
are based on series´ reports of and patient´s records from hospitals and dermatology 
departments. Moreover, it is necessary to take into account that the incidence of SS is 
determined by the incidence of infectious causes in general population (Hommel et al, 1993). 
With all these limitations, it has been reported that the incidence of SS in Scotland is 2.7 
cases per million inhabitants and year (Kemmett & Hunter, 1990).  
Gender distribution of SS is conditioned by the underlying or trigger disorder. There is a 
female predominance in parainflammatory and idiopathic cases which disappears in the 
infantile and paraneoplastic ones. There is no racial predilection. 
4. Pathogenesis 
The pathogenesis of SS remains to be definitively determined. Three possible pathogenical 
mechanisms have been considered, but none of them have been consistently demostrated 
(Requena, 2007): a) a type III hypersensitivity reaction, b) an activation of T cells by antigens 
or superantigens, and c) a disturbance of neutrophils´ function. It seems that genetic factors 
play a role since SS has been associated to several HLA, especially to Bw54 (Mizoguchi, 
1988). Because of female predominace in parainflammatory and idiopathic cases and both 
pregnancy and contraconceptive pills implication in some cases of SS, hormonal 
background can also be involved in the development of SS. 
Numerous cytokines are involved in the pathogenesis of this condition, including 
interleukins 1, 2, 3, 6, and 8 and gamma interferon, but the key substance is the granulocyte-
colony stimulating factor (G-CSF). The administration of G-CSF can result in an outbreak of 
SS and this substance is elevated in serum of patients with SS and its levels are directly 
related with the disease activity (Kawakami et al, 2004;  Ginarte & Toribio, 2010). 
5. Clinical manifestations 
5.1 Skin 
SS begins as an alarming feature for the patient because of its abrupt onset, the presence 
of general malaise, and the pain or tenderness of the multiple erythematoedematous 
plaques (Gunawardena et al 1975;  Kemmett & Hunter, 1990; Zamora et al 1990; Sitjas et 
al, 1993; von den Driesch 1994; Chan et al, 1994; Ginarte et al, 1997). The appearance of 
each individual lesion may be variable: the colour goes from vivid red to violaceus, 
sometimes with central paleness due to dermal edema. This edema can also be 
represented by pseudovesicular or true bullous lesions (figure 1). It is relatively frequent 
to oberve dome like lesions, especially on tenar and hypotenar eminences (in “mountain 
range”) (figure 2). Individual lesions can also be pustular. Up to a third of the lesions have 
an annular appearance. Plaque´s size is variable but the majority range between 1 and 10 
cm. The lesions are distributed bilaterally but asymmetrically. Common locations are face, 
neck, upper trunk, shoulders, and hands. On pretibial aspect of the legs, the lesions may 
exhibit a nodular morphology, which may be the clinical manifestation of a typical SS, a 
subcutaneous Sweet or an erythema nodosum (see forward). Pathergy may be present in 
up to 8% of the patients. 
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Fig. 1. Erythematous plaques with vesicular and bullous appearance due to a intense dermal 
edema. 
 
 
Fig. 2. The plaques on tenar and hypotenar skin have frequently a characteristic appearance 
of “montain range” 
5.2 Mucous membranes 
The mucous membranes are frequently involved, especially the ocular as conjunctivitis or 
epiescleritis (Gottlieb et al, 2008) (figure 3). Less frequent is the affectation of the oral 
mucosa, usually as aphtous ulcers. 
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Fig. 3. Epiescleritis in a patient with Sweet syndrome 
5.3 Laboratory findings 
Analytic alterations are very frequent and they can have diagnostic significance. The most 
typical but not constant alteration is leukocytosis with neutrophilia that only in the 50% of 
the patients exceed by 10.0 x103 cells/mm3. The majority of patients have the acute reactants 
(erythrocyte sedimentation rate and C-reactive protein) elevated and a third have mild 
alterations in urinary tests (haematuria, leukocyturia, and/or proteinuria) without 
affectation of renal function (Ginarte et al, 1997). It is necessary to distinguish the laboratory 
findings related to SS from the analytic changes due to trigger or associated diseases. For 
example, the presence of anemia, trombocytosis and/or massive leukocytosis should force 
us to rule out an haematologic malignancy (Cohen & Kurzrock, 1993). 
5.4 Extracutaneous manifestations 
Frequently patients with SS have extracutaneous manifestations that can be caused by two 
different mechanisms: a) a systemic neutrophilic reaction that affects not only the skin but 
also internal organs, and b) a disease or trigger condition causing the SS. These two different 
possibilities make more difficult the management of the patients because it is hard to 
distinguish by means the clinical and routine complementary tests if an internal disorder is 
the cause or the consequence of the SS. For example, the existence of respiratory 
manifestations, pulmonary infiltrates in X-ray chest, fever and leukocytosis with 
neutrophilia in a patient with SS set the doubt between an infectious pneumonia or a 
neutrophilic pneumonitis (which has important practical consequences since their treatment 
is quite different, i.e., antibiotics versus glucocorticoids). Despite of its original 
denomination as acute febrile neutrophilic dermatosis, the fever is only present in 50 to 72% 
of the cases (Ginarte et al, 1997). Joint involvement appear in 37 to 51% of the patients, 
usually as arthralgias or, more rarely, as true arthritis, which is commonly located on knees 
www.intechopen.com
 
Sweet Syndrome 
 
123 
and ankles. Neutrophilic infiltration of internal organs is less frequent. Although the 
infiltration of the majority of the organs has been reported, the most frequently affected are 
the lungs (up to 6% of the patient in a serie) (Sitjas et al, 1993). Pulmonary involvement 
expresses as neutrophilic alveolitis. In the literature there are abundant references about the 
neutrophilic affectation of internal organs, which may induce to think that it is a frequent 
event even though it is actually an uncommon fact. This situation is secondary to a bias in 
reporting the more extreme cases of SS. Nevertheless, the possibility of internal organ 
involvement in SS patients should always be taken in consideration and it is important 
distinguish it from other diseases or trigger factors (especially the infectious ones) since their 
clinical management is quite different. As neutrophilic internal organ involvement is 
relatively more frequent in paraneoplastic SS than in other subtypes of SS, its presence 
obligates us to rule out a malignancy (Cohen & Kurzrock, 1993). Table 3 shows the main 
extracutaneous manifestations of SS. 
 
ORGAN CLINICAL MANIFESTATIONS REFERENCES 
Bones  
Chronic recurrent osteomyelitis (in 
children) 
Majeed et al, 1989; 
Marie et al, 1998 
Bowel 
Neutrophilic bowel infiltration, 
pancolitis 
McDermott et al, 2001; 
Fain et al, 1996 
Central nervous 
system 
Neuro-Sweet 
Hisanaga et al, 1999; 
Nobeyama & Kamide, 
2003;  Ramos et al, 2003; 
Hisanaga et al, 2005; 
Sobol et al, 2009; 
Watanabe et al, 2009 
 
Heart 
Aortitis, myocarditis, cardiac 
insuficiency, isquemic cardiopathy  
Muster et al, 1983; 
Shimizu, 1998; Guia et 
al, 1999; Dorenkamp et 
al, 2003 
Kindney 
Glomerulonephritis, alterations of 
urinalysis 
Christ et al, 1996 
Liver 
Neutrophilic hepatitis, changes in liver 
function tests and analysis 
Kemmett & Hunter, 
1990; Zamora et al, 
1990; Fett et al, 1995; 
Ginarte et al, 1997 
Lung 
Neutrophilic alveolitis, pleural effusion; 
radiologic sterile infiltrates 
Cohen & Kurzrock, 
1992; Sitjas et al, 1993;  
Fett et al, 1995; Peters et 
al, 1998; Astudillo et al, 
2006 
Muscle Tendosinovitis, myositis, myalgias 
Attias et al, 1995; 
Brown et al, 2002 
 
Table 3. Systemic involvement in Sweet syndrome 
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6. Characteristics of the subsets of SS 
6.1 Idiopatic 
Clasically it is the most frequent subset of SS and it represents up to 70% of the cases in old 
series (Requena, 2007). It predominates in women, especially in patients aged under 45 
years. Most recently, this subset has become less prevalent possibly due to the better study 
of the patients (Corazza et al, 2008). 
6.2 Parainflammatory 
This group encompasses the SS associated or triggered by inflammatory and infectious 
conditions. There is a broad number of entities related with SS, some of them only based on 
isolated or few case reports, which makes difficult to assess the true power of the association 
(reviewed by Requena, 2007; von den Driesch, 1994;  Cohen, 2007). The best documented 
inflammatory diseases associated with SS are Beçhet disease, bowel inflammatory disease, 
rheumatoid arthritis, lupus erythematous, and other autoimmune collagenosis. The 
infectious conditions more related with SS are oropharingeal infection (especially due to 
streptococcus pyogenes) and intestinal infections by Salmonella and Yersinia. Less constantly 
SS has been linked to other bacterial infections, tuberculosis, lepra, histoplasmosis, 
toxoplasmosis, HIV, and viral hepatitis. Recent reports suggest that the patients with 
previous oropharingeal infection have a less severe form of this syndrome (Borges Da Costa 
et al, 2009). 
6.3 Paraneoplastic SS 
It is a well established subset of SS with an obvious interest. Up to 20% of SS are 
paraneoplastic (Cohen & Kurzrock, 1993). The SS may precede (sometime in years) or follow 
the malignancy. It also may arise in relation with the recurrence of previous malignancy. 
There are some characteristics more related to paraneoplastic than to non-paraneoplastic SS: 
a) lack of female predominance; b) advanced age; c) presence of anemia and/or other 
hematological disturbances; d) extracutaneous involvement; e) atypical, pustular, or necrotic 
skin lesions (Cohen & Kurzrock, 1993; Watanabe et al, 2009). The majority of paraneoplastic 
SS are associated with hematologic malignancies, especially with acute myelogenous 
leukemia and myelodysplastic syndromes (Buck et al, 2008). About 15% of paraneoplastic SS 
are related with solid cancers, predominating breast, gastrointestinal, and genitourinary 
origin. 
6.4 Drug-induced SS 
More than 25 drugs have been related to the flare of SS, but the most frequently implicated 
is the granulocyte-colony stimulating factor (G-CSF). Other drugs that are commonly 
associated with the development of SS are trimethoprim-sulphamethoxazole, oral 
contraceptive pills, retinoids, minocicline, hydralazine, carbamacepine, bortezomib, and 
imatinib. As it is usual in other skin eruptions induced by drugs, the disease fades with the 
withdrawal of the drug and flares up if it is re-administrated. 
6.5 SS associated with pregnancy 
It is not unanimously considered as a subgroup of SS, but its existence should be taken into 
account due to its relative frequency. 
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7. Clinical variations and associations with other dermatoses 
The typical cases of SS present very characteristics clinicopathological manifestations so that 
their diagnosis usually does not represent particular difficulty. Nevertheless, the SS may 
occasionally show a different clinical picture or it may be associated with other cutaneous 
signs making difficult to set the diagnosis and/or imply a change in the patient´s 
management. There is controversy about the need of describing such cases as “atypical” SS 
or as individualizing them as different entities. 
7.1 Overlap and relationship with other ND 
The group of ND represents a continuum of diseases that share clinical, histopathological, 
and causal features. The individualization of each entity is mainly based on clinical criteria. 
This fact explains that SS occasionally shares clinical characteristics with other ND (overlap), 
especially with generalized vesiculobullous forms of pyoderma gangrenosum. Other ND 
such as Behçet disese, bowel bypass syndrome, and neutrophilic eccrine hidradenitis may 
clinically resemble SS (Mizuashi et al, 2010). Sometimes patients with these features can only 
be diagnosed generically as suffering a ND, without a more specific denomination. In the 
same way, there have been reported patients suffering both SS and other ND (either 
simultaneously or sequentially) (Callen, 1985; Sherertz, 1987; Villanueva et al, 1989; Ginarte 
et al, 1997). 
7.2 Chronic recurrent annular neutrophilic dermatosis 
As its denomination indicates, it is a subtype of SS characterized by erythematoedematous 
plaques with a chronic and recurrent evolution. It has neither extracutaneous signs, nor 
fever or neutrophilia (Christensen et al, 1989; Romero et al, 1994; Cabanillas et al, 2008). 
7.3 Subcutaneous fat involvement 
Frequently, patients with SS have nodular lesions, especially on anterior aspects of the legs. 
These nodules are the clinical manifestation of the alteration of the subcutaneous fat, which 
can be originated by two different mechanisms. The first one called subcutaneous SS is 
characterized by a neutrophilic inflammatory infiltrate located on subcutaneous fat (either 
exclusively or accompanied by dermal affectation). Such infiltrate is usually located in fat 
lobules, but occasionally it may be septal or mixed (Cohen & Kurzrock, 2003). In a recent 
study, subcutaneous SS was shown by 16% of the patients (Abbas et al, 2010). The second 
possibility of subcutaneous fat involvement in SS is the association between this syndrome 
and erythema nodosum. This association is relatively frequent (up to 30% of the cases) and 
can be explained because both entities share several common features: essentially both are 
reactive dermatoses triggered by similar stimuli and pathogenically mediated by 
neutrophils. They are also treated with similar treatments (Ginarte et al, 1997; Ginarte & 
Toribio, 2000; Ginarte & Toribio, 2007). Due to the different significance of subcutaneous SS 
and erythema nodosum, it is necessary to make a deep biopsy from one of the nodules. 
7.4 Sweet syndrome in infancy 
About 16% of SS appears in children (Abbas et al, 2010). Pediatric SS is similar to that in 
adult population, with only three differences: a) it is associated with immunodeficiency 
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(HIV infection and other immune disorders), b) it is less associated with malignancy 
(although it is necessary to investigate this condition), and c) it is particularly susceptible to 
recurrences (Mohr et al, 2010). 
7.5 Located forms 
It has been described as located subtypes of SS cases with clinical lesions limited to a 
particular body´s area. The neutrophilic dermatosis of the dorsal hands shows 
characteristics as much SS as pyoderma gangrenosum exclusively located in this area. There 
is a controversy about if this entity is a subtype of SS or it is an independient disease 
(Walling et al, 2006; Laguna et al, 2007; Takahama & Kanbe, 2010). The same consideration is 
discussed about the located form in facial region (Whittle et al, 1968). 
8. Histopathology 
It is very characteristic and one of the diagnostic criteria of SS: a diffuse infiltrate of 
neutrophils located in the upper half of the dermis accompanied by intense edema. This 
edema causes the clinical appearance of pseudovesicular or bullous plaques. 
Leukocytoclasia is frequently present and may be prominent, but obvious vasculitis 
(neutrophils and fibrin deposits into blood vessel walls) must be absent in order to set the 
diagnosis. Ocasionally swollen endothelial cells, scattered eosinophils (more typical of drug-
induced SS), and epidermal exocytosis of neutrophils (even with formation of subcorneal 
pustules) can be observed. In older lesions the neutrophilic infiltrate is substituted by 
linfohistiocytic infiltrate  (Jordaan, 1989). Requena et al (Requena et al, 2005; Requena, 2007) 
have described the called histiocytoid Sweet syndrome, characterized by a dermal infiltrate 
constituted by immature neutrophilic granulocytes that have an appearance 
indistinguishable from histiocytoid cells on optic microscopy with routine stains. The 
majority of this histiocytoid SS is associated with hematological malignancies, although it 
has recently been reported an histiocytoid SS induced by trimethoprim-sulfamethoxazole 
therapy with bone marrow granulocytic maturation arrest (Wu et al, 2008) and two patients 
with inflammatory bowel disease (Requena et al, 2005; Spencer et al, 2008). 
Immunohistochemical analysis is necessary when histyocites are present in SS in order to 
distinguish histiocytoid SS (immature neutrophils) from true histiocytes that can be present 
in the typical neutrophilic infiltrate, sometimes in a moderate or predominant amount 
(specially in older lesions) (Corazza et al, 2008). 
9. Diagnosis 
Typical forms of SS are easily diagnosed by means of criteria of Su and Liu published in 
1986 (Su & Liu, 1986) (table 4). Von den Driesch provided a more evolved modification of 
these criteria in 1994 (von den Driesch, 1994) (table 5), but it has had less acceptation. As we 
previously indicated, there are patients with “atypical” SS, transitional forms of SS and 
other ND, as well as cases in which it is only possible to set a generic diagnosis of ND. 
10. Differential diagnosis 
As typical forms of SS exhibit a very characteristic clinicopathological picture they rarely 
cause problems with differential diagnosis. The disease that clinically more resembles SS is 
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the erythema multiforme. Other clinical differential diagnosis are drug eruptions and Behçet 
disease. All of these entities can be ruled out by means of a skin biopsy. Other ND (atypical 
pyoderma gangrenosum, bowel bypass syndrome, neutrophilic eccrine hidradenitis), 
vasculitis (specially erythema elevatum diutinum), and erythema nodosum may 
occasionally set problems with differential diagnosis both from the histopathological and 
clinical points of view. 
 
Major criteria 
 Clinic criterium: abrupt onset of tender or painful erythematous or violaceus plaques or 
nodules 
 Histopathological criterium: predominantly neutrophilic infiltration in the dermis 
without leukocytoclastic vasculitis 
 
Minor criteria 
 Preceded by fever or infections 
 Accompanied by fever, arthralgia, conjunctivitis, or underlying malignancy 
 Leukocitosis 
 Good response to systemic steroids and not to antibiotics 
The definite diagnosis of SS demands the fulfillment of both major criteria and at least two 
of the minor criteria 
Table 4. Diagnostic criteria by Su y Liu (1986) 
 
Major criteria 
1. Clinical criterium: abrupt onset of tender or painful erythematous plaques or nodules 
occasionally with vesicles, pustules or bullae 
2. Histopathological criterium: predominantly neutrophilic infiltration in the dermis 
without leukocytoclastic vasculitis 
 
Minor criteria 
1. Preceded by a nonspecific respiratory or gastrointestinal tract infection or vaccination 
or associated with: 
a. Inflammatory diseases such as chronic autoimmune disorders, infections 
b. Hemoproliferative disorders or solid malignant tumors 
c. Pregnancy 
2. Accompanied by periods of general malaise and fever (>38ºC) 
3. Three of four of the following laboratory values during onset: 
a. ESR > 20 mm 
b. C-reactive protein positive 
c. Segmented-nuclear neutrophils and stabs > 70% in peripheral blood smear 
d. Leukocytosis > 8000 
4. Excellent response to treatment with systemic corticosteroids or potassium iodide 
Table 5. Diagnostic criteria by von den Driesch (1992) 
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1. Non-steroidal anti-inflammatory drugs: indometacin, naproxen 
2. Tetracyclines: doxicycline, minocycline 
3. Dapsone 
4. Clofazimine 
5. Cyclosporine 
Table 6. Second-line therapies of Sweet syndrome. 
11. Treatment 
Nowadays, the first line therapies for SS are systemic corticosteroids, potassium iodide, 
and colchicine (Cohen, 2009). Systemic corticosteroids are the most widely used: the 
clinical response is so fast and brilliant that it is considered a diagnostic criterion (Su & 
Liu, 1986). The general malaise fades into hours and skin lesions into days (less than 10 
days) (von den Driesch, 1994). Oral prednisone is given at a dosage of 0.5-1 mg/kg/day 
(in a single dose or divided in two doses). The dosage is progressively lowered during 3-6 
weeks. Such brilliant response to prednisone is darken by the frequent recurrences: 20-
30% of the patients will suffer recurrences after treatment withdrawal and up to 10% of 
the cases will have a chronic and recurrent evolution for more than 1 year (Kemmett & 
Hunter, 1990; Sitjas et al, 1993, von den Driesch, 1994; Ginarte et al, 1997). The recurrences 
respond well to a new cycle of systemic corticosteroids (Ginarte et al, 1997), but their use 
is limited by their long-term side effects. Another limitation of systemic corticosteroids is 
the potential existence of an active infection that may trigger the SS. It is important to 
ruled out such possiblity. 
Potassium iodide is a therapy as fast and effective as systemic corticosteroids. In fact, the 
response to this agent was included in the diagnostic criteria by von den Driesch (von den 
Driesch, 1994). Systemic symptoms disappear within 24 to 48 hours and cutaneous plaques 
in as much as 1 week. The dosage of potassium iodide is 300 mg administrated orally, three 
times daily (or if it is used the Lugol saturated solution, 3 drops three times each day and 
then increasing progressively the dose to a maximum of 15 drops three times each day). The 
main adverse effects are gastrointestinal intolerance (nausea and/or diarrhea), 
hypotiroidism, and vasculitis (Horio et al, 1983). 
The other first-line therapy for SS is colchicine. This drug is administered at a dosage of 0.5 
mg, two or three times per day. It can be maintained from 2 to 4 weeks. About 90% of the 
patients respond favorably within a few days and its main limitation are the gastrointestinal 
side effects (nausea and/or diarrhea) (Maillard et al, 1999). 
There have been reported favorable responses to a wide and heterogeneous group of 
drugs. The response to several of these drugs is only based in isolated case reports, so it 
must be considered with caution. Table 6 summarized the drugs most repeatedly pointed 
out in the literature (isolated case reports are not included). These drugs are considered 
second-line treatments, but it is important to keep them in mind because they may be an 
effective therapy in patients with frequent recurrences, intolerance or adverse effects to 
the first-line treatments. This fact is especially applicable to elderly or polymedicated 
patients. 
Obviously, although it was not mentioned, it is also important to treat the underlying 
process when possible. 
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